ALNY Earnings
Latest Revenue1.3B
Latest Net Income164.5M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $1.23 | 1.3B | 164.5M | +66.9% | +323.6% |
| Q1 2026 | $1.55 | 1.2B | 206.0M | +96.4% | +1,207.1% |
| Q4 2025 | $1.41 | 1.1B | 186.4M | +84.9% | +316.9% |
| Q3 2025 | $1.91 | 1.2B | 251.1M | +149.3% | +319.5% |
| Q2 2025 | -$0.55 | 773.7M | -72228000 | +17.3% | -323.1% |
| Q1 2025 | -$0.14 | 594.2M | -18251000 | +20.2% | +73.1% |
| Q4 2024 | -$0.65 | 593.2M | -83763000 | +34.9% | +40.9% |
| Q3 2024 | -$0.87 | 500.9M | -111570000 | -33.3% | -173.7% |
| Q2 2024 | -$0.13 | 659.8M | -16889000 | — | — |
| Q1 2024 | -$0.52 | 494.3M | -65935000 | — | — |
| Q4 2023 | -$1.10 | 439.7M | -137870000 | — | — |
| Q3 2023 | $1.18 | 750.5M | 147.8M | — | — |
Alnylam Pharmaceuticals (ALNY) — Earnings